💉
COVID-19 Vaccines
12 articles analyzed — Average score : 47/100
Grade distribution
Authors' conclusions
Articles
B
Mostly reliable (67/100)
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. Positive
Sadoff J et al.·The New England Journal of Medicine·Jun 2021
B
Mostly reliable (64/100)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Positive
Polack FP et al.·New England Journal of Medicine·Dec 2020
B
Mostly reliable (62/100)
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. Positive
Voysey M et al.·Lancet·Jan 2021
C
Nuanced (51/100)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Positive
Logunov DY et al.·Lancet (London, England)·Feb 2021
C
Nuanced (50/100)
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. Mixed
Andrews N et al.·The New England journal of medicine·Apr 2022
C
Nuanced (48/100)
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Mixed
Lopez Bernal J et al.·The New England journal of medicine·Jul 2021
C
Nuanced (48/100)
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. Positive
Greinacher A et al.·The New England Journal of Medicine·Apr 2021
C
Nuanced (46/100)
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. Positive
Charmet T et al.·Lancet Regional Health – Europe·Jul 2021
D
Unreliable (44/100)
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Positive
Voysey M et al.·The Lancet·Jan 2021
D
Unreliable (31/100)
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. Positive
Oster ME et al.·JAMA·Jan 2022
D
Unreliable (30/100)
Surveillance for Adverse Events After COVID-19 mRNA Vaccination. Negative
Klein NP et al.·JAMA·Oct 2021
E
Not reliable (24/100)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Positive
Khoury DS et al.·Nature medicine·May 2021